
The US Food and Drug Administration (FDA) has put Diamyd Medical's planned phase III trial under a 'partial clinical hold'.
This means that the FDA hasn't been able to approve all parts of the Swedish company's application to begin the study. A lack of sufficient information concerning Diamyd's drug candidate is the cause, the FDA reports, according to a press release from Diamyd Medical.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app